Recent Updates
Recently added Catalysts
SIBN Positive Sentiment Score: 70/100

SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024

Key Takeaway: SI-BONE, Inc. has announced that it will report its financial results for the third quarter of 2024 on November 12, 2024, following market close. The company will host a conference call at 1:30 PM Pacific Time to discuss these results. SI-BONE is recognized for its innovative solutions in the treatment of sacropelvic disorders and has achieved significant milestones in minimally invasive surgical techniques. Investors can access the conference call through registration and find the webcast on the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE is a leader in surgical treatment for sacropelvic disorders.
  • Company has a robust track record with over 100,000 procedures.
  • Strong clinical evidence supports the effectiveness of their technology.

Full Press Release Details

SANTA CLARA, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/b8oqnu9r. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for the surgical treatment of sacropelvic disorders. Since pioneering minimally invasive surgery of the SI joint in 2009, SI-BONE has supported over 3,900 surgeons in performing more than 100,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 135 peer-reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation, and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.
Investor Contact: Saqib Iqbal investors@si-bone.com

Frequently Asked Questions

When will SI-BONE report third-quarter 2024 financial results?

SI-BONE will report its third-quarter 2024 financial results on November 12, 2024.

How can I access the SI-BONE conference call?

Investors can register for the conference call via the provided registration link.

What is the focus of SI-BONE, Inc.?

SI-BONE specializes in solving sacropelvic disorders through innovative medical devices.

How many sacropelvic procedures has SI-BONE supported?

SI-BONE has supported over 100,000 sacropelvic procedures performed by more than 3,900 surgeons.

Where can I find more information about SI-BONE's products?

Additional information about SI-BONE and its products is available on their website.

Last updated: Oct 22, 2024